-+ 0.00%
-+ 0.00%
-+ 0.00%

Vicore Pharma Q3 operating loss widens 15% to SEK 133.3 million

PUBT·11/05/2026 07:08:09
Listen to the news
Vicore Pharma Q3 operating loss widens 15% to SEK 133.3 million
  • Vicore Pharma’s third-quarter 2026 loss for the period widened 10% year over year to SEK 124.3 million.
  • Net revenues fell 25% year over year to SEK 600,000.
  • Cash, cash equivalents and short-term investments totaled SEK 772 million at September 30, 2026, down 34% from December 31, 2025.
  • In October, independent monitors recommended continuing the Phase 2b ASPIRE trial of buloxibutid without modification following a planned futility analysis.
  • ASPIRE topline results remain expected in mid-2027, with preparations advancing for a potential Phase 3 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicore Pharma Holding AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.